Growing focus on affordable healthcare is encouraging pharmaceutical companies to expand their biosimilar portfolios. Biosimilar erythropoietin products are creating additional options for healthcare providers and eligible patients. Market Overview The Erythropoietin Drug Market was valued at US$ 13.14 billion in 2025 and is projected to reach US$ 29.00 billion by 2034, registering a CAGR of...